Easton Pharmaceuticals, Inc. (EAPH)

[TheFinalCD]

NEW$ is ^^^^IMMINENT~~~



Womens "Viagra" product Launch=HUGE!!


ABSOLUTELY~~~HUGE!!!!!!!!!!!!!!!!!!!!{{{{{{ WOW }}}




Womens Viagra


HUGE!!!!!!!!!!!!!!!!!!!!!!!!!


Easton Pharmaceuticals(EAPH) Announces Projections of $15 Million in Revenue For 2012 From The Company's First Territory Launch of VIORRA in Mexico

http://www.marketwire.com/press-release/easton-pharmaceuticals-announces-viorra-regulatory-filing-mexico-expected-be-first-territory-otc-eaph-1536845.htm

VIORRA is a Female Over-The-Counter Aid for Treatment to Restore and Improve Vaginal Moisture and Elasticity Plus Increase Sexual Desire

TORONTO, ONTARIO, Jul 22, 2011 (MARKETWIRE via COMTEX) -- Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products has been advised of by BMV Medica S.A. de C.V. (BMV), the company that was recently retained in Mexico to finalize regulatory approval and arrange distribution partnerships for the company's first product launch in Mexico;

-- BMV Medica S.A. de C.V. (BMV) has advised that their initial market
analysis and conversations with distribution partnerships for the
company's first product launch, VIORRA an over-the-counter aid for the
treatment to restore and improve vaginal moisture and elasticity, that
also exhibits a very positive effect on women's sexual desire and
arousal FSAD (Female Sexual Arousal Disorder) could generate upwards of
$15 million dollars in revenue within twelve months of product launch.
-- Mexico represents an ideal first territory launch site for our VIORRA
Female Sexual Dysfunction (FSAD) product, stated John Easton, CEO and
Chairman of the board of Easton Pharmaceuticals, "As Male Sexual
Dysfunction products have historically done very well in Mexico, and
with a population of 120 million, the raw numbers of prospective female
customers are very attractive to Easton Pharmaceuticals. The world
market for these female conditions are estimated in excess of $2
billion."
-- BMV estimates the regulatory approval process will be completed in early
2012. In parallel with the regulatory filing, Easton Pharmaceuticals
under the guidance of BMV has begun talks with several large
distribution companies that are focused on sales and marketing in the
women's health market.

Easton Pharmaceuticals" believes that with both
the regulatory and commercial alliance initiatives running in parallel
will enable a timely, successful launch of VIORRA and generate upwards
of $15 million annual company revenue from Mexico beginning in 2012.